Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study
Currax Pharmaceuticals LLC (“Currax”) today announced top-line results from a Cardiovascular Health Outcomes Analysis (HOA). This study evaluated the cardiovascular safety of CONTRAVE®/MYSIMBA®, a weight management drug. The real-world study compared CONTRAVE®/MYSIMBA® to a similar product for the purpose of measuring major adverse cardiovascular events (MACE). The primary analysis included over 24,600 patients with an average…
